Last reviewed · How we verify
Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study
This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder in a Latin American population.
Details
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 28 |
| Start date | 2003-10 |
| Completion | 2005-05 |
Conditions
- Schizophrenia
- Schizoaffective Disorder
Interventions
- Ziprasidone
Primary outcomes
- Change from baseline to endpoint in Brief Psychiatric Rating Scale (BPRS) total score — Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO)
Countries
Mexico